Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
NU E Power Corp. Announces Completion of Unwinding its Acquisition of Blu Dot Systems Inc. (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Oncology Pharma Inc (EM) ONPH

Healthcare Biotechnology
Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus. The company was formerly known as SourcingLink.net Inc. and changed its name to Oncology Pharma Inc. in June 2019. Oncology Pharma Inc. was... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (EXPM:ONPH)

Oncology Pharma Conducting Interviews and Presentations with Investors to Pursue Next Steps to Forward The Development Process of Nanoemulsion Drug Delivery System

ACCESS Newswire July 12, 2022

Oncology Pharma Conducting All The Preparations to Take Steps to Forward The Development Process of Nanoemulsion Drug Delivery System

ACCESS Newswire June 29, 2022

Oncology Pharma Announces: Initial Feasibility Study of the Nanoemulsion Drug Delivery System is Complete and Results Have Met the Threshold for Moving Forward To the Next Steps of Development

ACCESS Newswire June 8, 2022

Oncology Pharma Advances Progress on Multiple Fronts Including Advanced Attention to Connect2Trials' Commercial Development

ACCESS Newswire May 9, 2022

Oncology Pharma Completes Feasibility Phase of its Licensed Nanoemulsion Drug Delivery System to Treat Cancer

ACCESS Newswire April 13, 2022

Oncology Pharma Reports on Progress with Ribera Solutions

ACCESS Newswire March 2, 2022

Oncology Pharma Releases Further Feasibility Studies, Data and Capacities

ACCESS Newswire February 23, 2022

Oncology Pharma Expands on Feasibility Studies and Data

ACCESS Newswire February 17, 2022

Oncology Pharma, Inc. and Regen BioPharma, Inc. Announce Intent to Jointly Fast Track Development of Modified mRNA anti-Cancer Vaccine

ACCESS Newswire February 14, 2022
View More News ››

Opinion & Analysis (EXPM:ONPH)

No current opinion is available.
View More Opinion ››

Bullboard Posts (EXPM:ONPH)

RE:ValiRx and TheoremRx - VAL201 - US$61M plus royalties

So is there any truth in this....?
Oldbaldy - October 22, 2023

ValiRx and TheoremRx - VAL201 - US$61M plus royalties

Dr Ken Sorensen, Chairman of TheoremRx We are delighted out latest fundraising od $250m has brought in multiple financial institutions as...
Carolpeters24 - July 26, 2022
View more Bullboard ››

Walker Lane Resources Ltd.

Walker Lane Resources Ltd.

Walker Lane Resources Ltd. engages in the acquisition and exploration of mineral properties in Canada. The company explores ...
View More »

Podcasts